Trial results
$PYXS — Micvotabart pelidotin (MICVO)
Pyxis Oncology, Inc. (PYXS) Micvotabart pelidotin (MICVO): trial results in Second-line and beyond recurrent/metastatic head and neck squamous cell carcinoma (2L+ R/M HNSCC), 2027.
The catalyst
"Updated overall survival data from the MICVO monotherapy study are expected in the first half of 2027."
— Pyxis Oncology, 8-K filed 2026-09-09 · the filing. Checked word for word against the stored document when this page was built; a sentence that did not check out would not be here.
- Event id
PYXS-MICVOTABARTP-2026- Company
- Pyxis Oncology, Inc.
- Kind
- Trial results
- Indication
- Second-line and beyond recurrent/metastatic head and neck squamous cell carcinoma (2L+ R/M HNSCC)
- Window
- 2027-01-01 – 2027-06-30
- Status
- slate
The bar
No bar has been published for this event yet.
Verdicts
Sealed with the bar. Any verdict for this event reaches this page on 2027-07-30; subscribers get it on the day.